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Abstract: The clinical benefits of endocrine therapy for patients with hormonosensitive breast 
cancer are well established. For many years, 5 years of tamoxifen was the gold standard of 
adjuvant treatment. The recent development of new endocrine agents provides physicians with a 
more effective therapeutic approach. Nevertheless, the success of neoadjuvant endocrine therapy 
is much more recent and less reported in the literature. This article reviews the studies published 
about neoadjuvant endocrine treatment (tamoxifen and aromatase inhibitors). According to 
the literature, neoadjuvant endocrine therapy seems to be effective. In contrast to neoadjuvant 
chemotherapy, neoadjuvant endocrine therapy is well tolerated, with very few patients having 
to discontinue the treatment because of side effects. It does not constitute a standard treatment 
but could have potential for elderly women with operable, hormonosensitive, well differentiated 
and slowly progressing (SBR I) tumor or for patients with lobular MSBR 1 carcinoma (low 
chemosensitivity). The newer generation of aromatase inhibitors (letrozole, anastrozole, 
exemestane) appears to be more active (in terms of overall response rates and conservative surgery 
rate) than tamoxifen. Patients with an estrogen receptor Allred score of 6 and over are more likely 
to respond and gain a clinical benefit. The optimal duration of neoadjuvant therapy has not yet 
been investigated in detail. These preliminary results should be confirmed by further studies.
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Background
History of endocrine therapy
The use of endocrine therapy for breast cancer dates back to the nineteenth century, 
when oopherectomy was first shown to cause regression of advanced breast cancer in 
premenopausal women.1 During the twentieth century, endocrine therapies evolved to 
include adrenalectomy, hypophysectomy, estrogens and androgens. In the early 1970s, 
tamoxifen, a competitive antagonist-agonist, was introduced, and the management of 
hormone-receptor breast cancer was changed. For many years, 5 years of tamoxifen was 
the gold standard of adjuvant treatment and has largely contributed to the effectiveness 
of such therapy. The recent development of new endocrine agents – the newer generation 
aromatase inhibitors: letrozole, anastrozole and exemestane – provides physicians with 
a more effective therapeutic approach, in metastatic disease or in the adjuvant setting 
of breast cancer patients.2
Mechanism of action of tamoxifen
Tamoxifen, a selective estrogen receptor (ER) modulator, is a competitive inhibitor of 
estradiol binding to the ER. It has mixed agonist and antagonist effects. The agonist International Journal of General Medicine 2009:2 130
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effects of tamoxifen can be beneficial, since they may help 
prevent bone demineralization, but are also detrimental in 
that they are associated with increased risks of uterine cancer 
and thromboembolism, and may play a role in development 
of tamoxifen resistance.3–6
Mechanism of action of aromatase 
inhibitors
In the premenopausal woman, estrogen synthesis takes place 
mainly in the ovaries. After menopause, estrogens are synthe-
tized mainly by conversion of androgenic substrates via the 
aromatase enzyme in the skin, fat, and muscle. The aromatase 
enzyme has been demonstrated to be present in peripheral 
tissues as well as in breast tissue, and in breast tumor tissue. 
The aromatase inhibitors suppress plasma estrogen levels 
by inhibiting or inactivating aromatase, and therefore have 
none of the agonist activities of tamoxifen.7
Classification of aromatase inhibitors
Aromatase inhibitors are divided into two categories: type 1 
inhibitors, which are steroidal analogues of androstenedione 
and bind irreversibly to its site of action; and type 2 inhibitors, 
which are nonsteroidal, and bind reversibly to a heme group 
in the activation site of the enzyme. Aromatase inhibitors are 
further characterized as first-, second- and third-generation 
according to the chronological order of their clinical 
development (Table 1).
The first-generation aromatase inhibitor, aminoglutheti-
mide (Orimetene®), became available for use in treatment 
of breast cancer in the late 1970s. The second-generation 
aromatase inhibitors include formestane (Lentaron®), a type 1 
inhibitor, fadrozole and roglethimide, type 2 inhibitors. While 
each of these has exhibited clinical efficacy, significant side 
effects limited their utility.8–10 The third-generation inhibitors 
were developed in the early 1990s, and include the type 1 
inhibitor exemestane (Aromasin®), as well as the type II 
inhibitors anastrozole (Arimidex®) and letrozole (Femara®). 
These three agents have demonstrated high promise for 
their effects in the metastatic, adjuvant and neoadjuvant 
settings.7
Until recently, neoadjuvant therapy of breast cancer has 
used predominantly cytotoxic chemotherapy. Neoadjuvant 
therapy reduces the size of bulky tumors and a conservative 
surgery can be proposed to the patients instead of a mastec-
tomy. Endocrine treatment is now emerging as an attractive 
alternative in hormone receptor positive postmenopausal and 
mainly elderly women, many of whom could not tolerate the 
toxicity of chemotherapy.11 So, the success of neoadjuvant 
endocrine therapy is much more recent and less reported 
in the literature. Respective indications of chemotherapy 
and hormone therapy as primary treatment are not fully 
established.
Thus, our aim was to review the clinical data of the 
main published studies using neoadjuvant hormonotherapy 
and to compare tamoxifen to letrozole, anastrozole and 
exemestane.
Studies with tamoxifen (see Table 2)
Neoadjuvant endocrine therapy was initially assessed in 
elderly patients with locally advanced breast carcinoma.12 
In early studies, tamoxifen was used, but patients were not 
selected on the basis of patient selection with positive ER or 
progesterone receptor (PgR) breast cancers to identify those 
most likely to respond.
Many phase II studies were conducted,13 but only a few 
randomized phase III studies have been published.14–18 The 
comparison was mainly tamoxifen as sole therapy versus 
successive classical treatments. This approach does not 
correspond to the classical definitions of a neoadjuvant 
approach and furthermore is not accepted ethically in all 
countries.
Tan et al conducted a prospective randomized phase II 
study in 108 locally advanced primary breast cancer and 
premenopausal patients.14 This trial compared multimodal 
therapy (neoadjuvant chemotherapy, modified radical 
mastectomy, postoperative radiotherapy and adjuvant 
tamoxifen) versus tamoxifen alone. After a median follow-up 
of 52 months, there was no statistically significant difference 
in the rates of overall and disease-free survival between the 
two therapy groups. However, the time to first locoregional 
failure was significantly shorter in the hormone therapy alone 
group than in the multimodal therapy group.
Some other randomized trials have compared primary endo-
crine therapy with tamoxifen alone with surgery ± tamoxifen 
Table 1 Classification of aromatase inhibitors
First generation Second generation Third generation
Nonsteroidal Aminoglutethimide rogletimide, fadrozole, Anastrozole, letrozole, vorozole,
Steroidal formestane exemestaneInternational Journal of General Medicine 2009:2 131
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in elderly patients.15–18 In two of the studies,15,16 tamoxifen 
was compared with immediate surgery alone, and in the other 
two, tamoxifen was compared with surgery and tamoxifen.17,18 
After median follow-up of 34 to 72 months, there were no 
statistically significant differences in the rates of overall 
and/or disease-free survival between the two therapy groups. 
However, again, the time to first locoregional reccurrence was 
significantly shorter in the tamoxifen alone arm, as would be 
expected.
This approach of tamoxifen alone is predominant in the 
United Kingdom and in some Latin European countries, often 
linked to social and financial considerations. However, it 
should be linked to positive hormone receptors, as evidently 
patients with negative receptors do not benefit from this 
therapy. Furthermore a local relapse is not an incidental 
event, and can be avoided in most patients.
Another strategy is the true neoadjuvant approach to 
initiate endocrine therapy in order to prepare a secondary 
local treatment, with the objective of breast conservation, 
as has been shown with neoadjuvant chemotherapy. It is 
recognized that steroid receptor positivity is predictive of 
response to hormonal manipulation, as well as in adjuvant 
treatment19 or in a palliative setting.20 So it seemed possible 
to propose a neoadjuvant hormonal treatment for women 
with a tumor that was too large to be treated by conserva-
tive surgery (generally 3 cm in diameter, or more) and 
who met the criterion of response to hormonal treatment. 
Mauriac et al21 have published a retrospective study of 
199 women aged from 50 to 70 years treated by neoadju-
vant tamoxifen and whose tumor expressed steroid recep-
tor positivity. Conserving surgery rates after neoadjuvant 
tamoxifen were 54% and 44% for operable and for locally 
advanced tumors, respectively. This approach, which is 
currently used in elderly patients, seems to be applicable 
in younger women.21 These younger women should have 
been first menopaused by surgery, radiotherapy or with 
LH-RH analogues.
In Edinburgh, small studies have been performed 
comparing neoadjuvant tamoxifen with aromatase inhibitors. 
Although patients were not randomized and the numbers 
were small, impressive results were achieved. As reported 
by Dixon et al,11 46% of patients treated with tamoxifen had 
reductions in tumor volume of more than 50% as assessed by 
ultrasound scan, versus 88% of patients treated with letrozole 
and 78% of patients treated with anastrozole.
A potential problem when using tamoxifen as neoadjuvant 
therapy is the long time period required to reach steady state 
plasma levels, up to 5 weeks. In contrast, the newer aromatase 
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inhibitors build up rapidly, reaching therapeutic concentra-
tions within days.11
Studies with letrozole (see Table 3)
The first reported study to investigate the neoadjuvant use 
of letrozole in patients with untreated locally advanced or 
large operable breast cancer was conducted by Dixon et al22 
The demonstration that letrozole was superior to megestrol 
acetate (Megace®) and aminoglutethimide in second-line 
treatment supports the belief that the neoadjuvant situation 
is amongst the best to investigate efficacy of letrozole. In a 
phase I study, Dixon et al treated 24 postmenopausal patients 
with either 2.5 or 10 mg of letrozole during 3 months to 
investigate its efficacy used as primary neoadjuvant therapy. 
All 24 patients were ER-positive. There were 5 complete 
clinical responses (CR) and 7 partial clinical responses (PR) 
in the patients treated with 2.5 mg letrozole, and 9 partial 
responses and 3 patients with stable disease in patients treated 
with 10 mg letrozole. There was no significant difference 
in clinical response between the two doses. Assessed by 
ultrasound and mammography, the 12 patients treated with 
2.5 mg had 1 complete response, 9 partial responses and 2 had 
no change. In the 12 patients treated with 10 mg letrozole, 
there were 8 partial responses and 4 with no change. One 
patient treated with the 2.5 mg dose had a complete clinical 
and pathological response. This study demonstrates high 
response rates in patients treated with letrozole at either 
2.5 mg or 10 mg dose, with significant numbers of patients 
achieving complete clinical responses within 3 months. 
Besides, this short period of treatment reduced tumor volume 
such that 15 patients who, at treatment onset, were considered 
to require mastectomy, were eligible for breast conserva-
tion after 3 months. All patients then underwent success-
ful conservation surgery and only one adverse event was 
reported throughout the whole 3-month course of treatment 
(pale stools). This short term study cannot determine whether 
neoadjuvant letrozole treatment is associated with any survival 
or disease-free survival benefit. These results on responses 
should be confirmed in further studies, because several weeks 
of letrozole are needed before a therapeutic steady-state is 
reached, because of the pharmacokinetics of this drug.
Miller et al23 conducted a study in postmenopausal 
women with large primary ER-rich (20 fmol/mg protein) 
breast cancers. They had been treated neoadjuvantly with 
either letrozole (2.5 mg daily, n = 12 or 10 mg daily, n = 12), 
anastrozole (1 mg daily, n = 12 or 10 mg daily, n = 11), or 
tamoxifen (40 mg daily, n = 24). After 3 months of treatment, 
the two aromatase inhibitors were more likely to produce 
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major tumor shrinkages (50% reduction in volume): 88 and 
70% for letrozole and anastrozole, respectively, compared 
with tamoxifen (46%). This difference between aromatase 
inhibitors and tamoxifen was significant (p  0.0001). 
For pathological responses, most tumors treated with 
aromatase inhibitors demonstrated a partial pathological 
response; the only tumor showing a complete pathological 
response was after treatment with letrozole. No adverse 
events were reported. Tumors from the same cohorts were 
also stained with antibodies against Ki67 (a marker of cell 
cycle/proliferation) and PgR (a marker of estrogen action). 
Immunohistochemical staining for Ki67 and PgR provided 
objective measures of major biological effects of therapy and 
differences between the aromatase inhibitors and tamoxifen. 
Letrozole and anastrozole treatment was associated with 
a reduction in Ki67 staining. This could be interesting 
since a reduction in Ki67 staining means a reduction of 
tumor proliferation. This effect was present irrespective of 
whether there was a clinical/pathological response. Similar 
reductions in Ki67 score were reported after treatment with 
tamoxifen but occasionally paradoxal increases in Ki67 
score were seen. Although the rise was not associated with 
clinical/pathological response, this effect could be due to the 
accumulation of tamoxifen-resistant highly proliferative cells. 
Treatment with letrozole and anastrozole was associated to 
fall in score of PgR in positive patients. In contrast, treat-
ment with tamoxifen was associated with a decrease in PgR 
in only 4 of 20 evaluable cases; the most common effect 
was an increase in PgR staining. Since PgR is regarded as a 
marker of a functional estrogen signaling pathway, the effect 
was consistent with the estrogen deprivation mechanism of 
action of these aromatase inhibitors.
These good results have led to further studies. 
A randomized, double-blind, multicenter study (P024 trial) 
was conducted to compare the anti-tumor activity of letrozole 
versus tamoxifene in 337 postmenopausal women with 
ER and/or PgR positive primary untreated breast cancer.24 
Patients were randomly assigned once daily treatment with 
either letrozole 2.5 mg or tamoxifene 20 mg for 4 months. 
At baseline, none of these patients was considered candidate 
for breast-conserving surgery (BCS) and 14% of the patients 
were considered inoperable. The primary endpoint was to 
compare overall objective response (CR + PR) determined 
by clinical palpation. Secondary endpoints included overall 
objective response on ultrasound and mammography and 
the number of patients who qualified for BCS. The overall 
objective response rate was statistically significantly superior 
in the letrozole group, 55% compared to tamoxifen, 36% 
(p  0.001). Secondary endpoints of ultrasound response, 
35% versus 25% (p = 0.042), mammographic response, 
34% versus 16% (p  0.001), and BCS, 45% versus 35% 
(p = 0.022) between the letrozole and tamoxifen groups, 
respectively, showed letrozole to be significantly superior. 
Moreover, both treatments were well tolerated.
Tumor response in this study was related to ER and PgR 
status.25 There were significantly more responses in patients 
subsequently confirmed to have ER-positive tumors than in 
patients who on subsequent testing had ER-negative tumors. 
In each of the ER categories, response rates were higher for 
letrozole than tamoxifen. Besides, Ellis et al have studied 
the expression of erbB1 and erbB2 according to the tumors. 
There was a high difference in response rates in tumors 
that were ER-positive and also overexpressed erbB1 and/or 
erbB2, with an 88% response rate in this group for letrozole 
versus a 21% response rate to tamoxifen (p = 0.0004). In 
contrast, in ER-positive tumors which did not overexpress 
erbB1 and/or erbB2, response rates were similar: 54% for 
letrozole versus 42% for tamoxifen (p = 0.078).
Another study has been reported by Wagnerova et al26 
Twenty-two postmenopausal ER- and/or PgR-positive 
women in clinical stage IIIB were treated with neoadjuvant 
oral letrozol 2.5 mg for 4 months. The primary endpoint was 
to evaluate overall objective response (CR + PR) determined 
by clinical examination. Wagnerova et al reported an overall 
response rate of 67%, with 8% CR. These results are similar 
to those of Eiermann et al.24
As the overall objective response rate of the P024 study 
was high with 4 months of letrozole, Paepke et al27 wanted 
to test the hypothesis of whether longer treatment would 
further increase the benefit for the patients. Thus, an open 
clinical trial was conducted with a total of 33 patients. 
They received letrozole 2.5 mg daily for a minimum of 4 
and a maximum of 8 months prior to surgery. Paepke et al 
reported that a longer treatment resulted in a statistically 
significant increase in tumor size reduction (p = 0.0393). 
Moreover, 90% of the patients receiving pre-operative 
treatment longer than 4 months had CR or PR compared to 
57% of patients with CR or PR receiving treatment up to 
4 months, suggesting that prolongation of the neoadjuvant 
endocrine treatment might present an encouraging thera-
peutic option. In the same way, Renshaw et al28 conducted a 
study in which 142 postmenopausal women were enrolled 
to receive letrozole 2,5 mg per day. Clinical response was 
assessed at 3 months. Nonresponders and patients whose 
tumors had become operable with a conservative surgery 
proceeded to surgery. The others continued letrozole for International Journal of General Medicine 2009:2 134
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at least a further 3 months. Some of these were still taking 
letrozole at 12 months. At 3 months, there were 9.5% CR, 
by 6 months, 29% and by 12 months 36%. The authors 
concluded that patients whose tumors are responding to 
letrozole at 3 months can expect further reduction in tumor 
volume with continued treatment.
In a newer Edinburgh study,11 83 patients were treated for 
3 months with neoadjuvant letrozole. They were subdivided 
according to their ER Allred score.29 This score varies from 
0 to 8, according to the intensity of positive tumor cells and 
to the proportion of positive-staining tumor cells. Dixon et al 
correlated clinical and ultrasound responses and change in 
tumor volumes in these patients in relation to the ER Allred 
score. Sixty of the tumors were ER category 8 and 23 were 
category 6 or 7. Response rates were similar in ER categories 
8 and 6 + 7 (80% and 74%, respectively), but there was a 
greater percentage reduction in tumor volume in patients 
whose tumors had the highest ER level. This difference was 
significant.
Studies with anastrozole (see Table 4)
Dixon et al30 evaluated, in a phase I study, the toxicity of 
anastrozole as neoadjuvant therapy in postmenopausal 
women with ER-rich (Allred score from 5 to 8), locally 
advanced or large (3 cm), operable breast cancers. Data 
on efficacy of the treatment were also reported. Twenty-four 
eligible patients were recruited into the study and received 
either 1 mg or 10 mg of anastrozole daily over a 3-month 
period. There were no serious adverse events, and only 
1 patient withdrew because of headaches, depression, and 
tiredness. Median reductions in tumor volumes as measured 
by ultrasound for those patients with a measurable 12-week 
assessment were 80.5% and 69.6% for anastrozole (1 and 
10 mg, respectively) after 12 weeks of treatment and 75.5% 
when both doses were grouped together. Besides, of these 
patients, 11 of 12 given 1 mg and 7 of 11 (1 patient eligible for 
the study withdrew because of adverse events) given 10 mg 
of anastrozole were found on ultrasound to have a 50% 
reduction in tumor volume after 12 weeks of treatment. Of 
the 17 patients who would have required a mastectomy at 
initiation of treatment, 15 were suitable for conservative 
surgery after anastrozole treatment. In general, treatment 
was well tolerated in this study.
The tumors treated in this study have recently been 
stained for erbB2 or Her2.31 Her2 is an oncogene which 
belongs to the growth factor receptors family with tyrosin 
kinase activity. The expression of the protein appears 
in 15% to 30% of breast cancer. In 22 of 24 patients 
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treated in this study, erbB2 status prior to treatment, and 
Ki67 and PgR before and after treatment were assessed. 
There were 6 erbB2 3+ tumors, the other 16 tumors being 
either negative or 1+. There was no difference in clinical 
response in relation to erbB2 status and changes in Ki67 
and PgR did not differ between the two groups. These are 
the first data demonstrating the clinical and the biological 
effectiveness of anastrozole in erbB2-positive, ER-positive 
breast cancers.
Milla-Santos et al32 treated 112 hormone-dependent 
locally advanced breast cancer postmenopausal women with 
anastrozole (1 mg) during 3 months. They reported 55% CR 
and 29% PR. Patients with a PR or a CR (n = 93) underwent 
surgery. Among these patients, Milla-Santos et al reported 
12% of pathological complete response (disappearance of 
all tumoral spread) and 71% of pathological partial response 
(51% to 99.9% reduction in tumoral spread). Patients who 
showed no response to neoadjuvant treatment underwent 
radiotherapy. No adverse events were reported.
We should mention for the record the study of Miller 
et al23 (see previous discussion on letrozole).
Smith and Dowsett 33 reported a multicenter, randomized, 
double-blind clinical trial: the Immediate Preoperative 
Arimidex Alone or in Combination with Tamoxifen 
(IMPACT) study. It compared anastrozole 1 mg daily versus 
tamoxifen 20 mg daily versus anastrozole plus tamoxifen. 
Three hundred and thirty postmenopausal patients with 
large or operable ER- and/or PgR-positive breast cancers, or 
potentially operable but locally advanced, were recruited. In 
this study, treatment was for 3 months and patients continued 
on the same endocrine treatment as adjuvant therapy for 
5 years if they responded. Primary endpoints were objective 
tumor response rates, with secondary endpoints being breast-
conserving rate and assessment of key biological markers 
including proliferation, hormone receptors and apoptotic 
rate.11 Smith and Dowsett reported a similar clinical response 
rate in the anastrozole arm (37%) in comparison with the 
tamoxifen arm (36%) or in the combination arm (39%). 
Patients who had received anastrozole underwent a signifi-
cantly more conservative surgery than these who had received 
tamoxifen (46 versus 22%, p = 0.03). In erbB2-positive tumor 
patients, there was a tendency for the clinical response rate 
to be increased in anastrozole arm compared to tamoxifen 
arm, but it was not signicant (58 versus 22%, p = 0.09). For 
letrozole, these results suggest that anastrozole could be 
prefered to tamoxifen for erbB2-positive tumor patients.
Similarly, a second neoadjuvant comparison of 
anastrozole and tamoxifen did not show superior response 
rates when anastrozole was used.34 The PROACT trial 
included 451 postmenopausal women with an ER-positive 
primary breast cancer. These patients were randomized to 
receive preoperative anastrozole (n = 228) versus tamoxifen 
(n = 223) for a duration of 12 weeks followed by surgery. The 
primary endpoint of this trial was response rate by ultrasound, 
defined as shrinkage 30% of largest tumor diameter. 
Response rates were 39.5% for anastrozole and 35.4% for 
tamoxifen (p = 0.29). As 137 patients in this trial received 
concomitant neoadjuvant chemotherapy, a subgroup analysis 
of patients on endocrine therapy alone was performed and 
showed response rates of 36.2% versus 26.5% in favor 
of anastrozole (p = 0.07). Contrary to expectations, the 
neoadjuvant IMPACT and PROACT studies did not mirror 
the results generated by the corresponding ATAC adjuvant 
trial, where anastrozole did prove superior to tamoxifen.35 
This result can perhaps be explained by the limited duration 
of therapy in the IMPACT and PROACT studies.
Studies with exemestane (see Table 5)
Dixon et al36 have evaluated, in a phase II study, the effect 
of neoadjuvant exemestane in 13 postmenopausal women 
with histologically or cytologically confirmed breast cancer. 
Tumors were 3 cm in diameter, ER+, bidimensionally 
measurable, operable, and locally advanced. Exemestane 
25 mg daily was given for up to 3 months after which 
definitive surgery was performed. Median reductions in 
clinical, mammographic and ultrasound tumor volume were 
85.5%, 84% and 82.5%, respectively. Before treatment with 
exemestane, 10/12 patients (1 patient died at the end of the 
treatment) would have required mastectomy; after treatment, 
2 had mastectomy and 10 had breast conservation surgery with 
clear margins. The most common adverse events were fatigue, 
insomnia and paresthesia, each reported in 3 patients.
In order to increase the pathological response rate, 
the exemestane-chemotherapy association as neoadjuvant 
treatment has been evaluated in 2 phase I studies.37,38 Recent 
preclinical studies provided first evidence that exemestane 
confers high cytotoxic potential to subtoxic doses of 
epirubicin when given concomitantly, suggesting that 
treatment with exemestane and epirubicin might be a safe 
and effective treatment for breast cancer. Thus, Wolf et al 
have treated 14 locally advanced breast cancer patients with 
exemestane 25 mg daily associated with 3 increasing doses of 
epirubicin (25, 30 and 35mg/m2/week) during 8 to 12 weeks. 
Ten out of 14 patients were evaluable. Wolf et al reported 
2 CR, 4 PR, 3 stable diseases and 1 progression. Nine out 
of 10  patients underwent surgery. A conservative surgery International Journal of General Medicine 2009:2 136
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has been conducted on 6 patients (66%). Of 10 patients, 
one presented a complete pathological response and the 
other presented a partial pathological response. As this 
combination seemed to be effective, a phase II study has 
been proposed.
In the same way, Lichtenegger et al38 have conducted a 
phase I study on 11 locally advanced breast cancer patients 
with exemestane 25 mg daily associated with 3 increasing 
doses of docetaxel (20, 25 and 30 mg/m2/week) over 8 to 
12 weeks. Nine out of 11 patients were evaluable. They 
reported 78% of partial clinical responses and 22% of stable 
disease. Pathological response rates were high with 78% of 
grade 1 and 22% of grade 2, according to the Chevallier et al 
classification.39 As this combination seemed to be effective 
too, a phase II study has been begun.
Gil et al40 have conducted a phase II study in 33 
postmenopausal breast cancer patients. The aim of the study 
was to evaluate the efficacy of exemestane as neoadjuvant 
therapy as a primary endpoint. At baseline all patients were 
considered ineligible for breast-conserving surgery. They 
were treated with exemestane 25 mg daily for 6 months. 
The radiological response was measured using RECIST 
criteria. On the 28 evaluable patients, 50% were in PR, 45% 
presented a stable disease and 5% were in progression. In all, 
15 patients have been operated on: 5 underwent a mastectomy 
and 10 had a conservative surgery.
In the same way, Krainich et al41 reported a phase II study 
with exemestane. Twenty-nine patients have been treated with 
25 mg daily exemestane for 16 weeks. Twenty-seven patients 
were evaluable: partial clinical response was registred in 37% 
of patients and 63% of patients presented stable disease. No 
complete pathological response was registred.
In another phase II study reported by Tubiana-Hulin 
et al42 38 postmenopausal women with ER-positive operable 
breast cancer have received 4 to 5 months of neoadjuvant 
exemestane (25 mg/day) before surgery. Tumor response 
was evaluated using RECIST criteria on the first 31 patients: 
there were 5.9% of clinically CR, 64.7% of PR and 23.5% 
of stable disease. Breast conserving surgery was achieved 
in 45.2%.
Discussion and prospects
According to the literature, neoadjuvant endocrine therapy 
seems to be effective. The clinical data (overall response 
rates, conservative surgery) reported when newer generation 
aromatase inhibitors are used appear to be better than with 
tamoxifen. Moreover, endocrine therapy is well tolerated. After 
a review of the literature, several facts merit discussion.
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Hormone receptors
The data indicate that selection for neoadjuvant endocrine 
therapy should be based primarily on ER status. Indeed, 
patients who are treated with neoadjuvant endocrine therapy, 
with an ER Allred score of 6, and over are most likely to 
respond and gain a clinical benefit.11 Furthermore, aromatase 
inhibitors produce responses in tumors with lower levels of 
ER whereas tamoxifen does not.25 Thus, it would be interest-
ing to assess the predictive value of ER Allred score as well 
for tamoxifen and for aromatase inhibitors. These analyses 
are not are not available will have to be conducted in specific 
trials. Conversely, according to the study of Buzdar et al43 
patients with an ER-positive tumor had a four times higher 
rate of pathological response to neoadjuvant chemotherapy 
than patients who with an ER-positive tumor.
Biological data
Immunohistochemical staining for Ki67 and PgR provided 
objective measures of major biological effects of therapy and 
differences between the aromatase inhibitors and tamoxifen. 
In contrast to tamoxifen, letrozole and anastrozole treatment 
was associated with a reduction in Ki67 and PgR stain-
ing. Although this effect was irrespective of the clinical/
pathological response,23 further studies should be conducted 
with more patients and a to establish a correlation between 
these biological modifications and response. Moreover, it 
seems that aromatase inhibitors are effective in both erbB2-
positive and -negative cancers while tamoxifen is less effec-
tive in erbB2-positive tumors.25,33 Indeed, in vitro studies have 
shown evidence for cross-talk and interaction between the 
ER and Her2 pathways. Previous studies have demonstrated 
that estrogen downregulates Her2 expression, tamoxifen may 
upregulate the transcription of Her2, and transfection with 
the Her2 coding region in MCF-7 breast cancer cells which 
are ER-positive and responsive to tamoxifen may lead these 
cells to become unresponsive to tamoxifen.44–46 According to 
the litterature, there are different causes of resistance: loss 
or decline of ER expression; ER mutations leading to desen-
sitization to hormonal agents; change in cofactor levels in 
resistant cells; and Her2 overexpression. From these results, 
it appears that Her2 plays an important role in resistance to 
hormonal therapy. Consequently, it would be interesting to 
evaluate different inhibitors of Her2 and related epidermal 
growth factor family receptors in association with hormonal 
therapies.
Other biomarkers could be discovered, particularly 
for gene expression. Thus and on the basis of preliminary 
studies, a phase II neoadjuvant letrozole study has been 
funded by the National Cancer Institute to examine gene 
expression profiles at baseline, 1 month and at surgery in 
patients receiving 4 months of endocrine treatment.47 The 
preliminary data show that about 20 genes exhibit a marked 
decrease in mRNA expression with neoadjuvant letrozole 
from samples taken at baseline and 1 month from the tumor. 
These decreases constitute early indices of the effectiveness 
of endocrine therapy, and the absence of these changes early 
on in therapy can easily be imagined to be indicative of 
primary resistance to therapy.
Duration of neoadjuvant therapy
Standard practice with neoadjuvant chemotherapy is to 
administer between 3 and 6 cycles prior to surgery, a 
time period felt sufficient to delineate responders from 
nonresponders. The optimal duration of neoadjuvant therapy 
has not been investigated in detail. Nevertheless, Paepke 
et al27 have reported that patients treated for 8 months with 
letrozole presented a statistically significant increase in 
tumor size reduction (p = 0.0393) compared to those who 
was treated for only 4 months. Furthermore, in another 
study,34 the authors concluded that patients whose tumors 
are responding to letrozole at 3 months can expect further 
reduction in tumor volume with continued treatment (9.5% 
CR at 3 months versus 36% at 12 months). Then the optimal 
duration of treatment may be longer than with chemotherapy, 
the mechanism of action appearing to be linked to a slower 
process. However, clinical surveillance appears mandatory, 
as there is always a risk of regression during treatment and 
before surgery.
For almost all the studies we have mentioned, the follow-up 
was too short to determine if aromatase inhibitor treatment is 
associated with any survival or disease-free survival benefit. 
Such results could be published subsequently. Nevertheless, 
the population of patients who are treated with neoadjuvant 
endocrine therapy tends to be elderly and these patients can 
have significant comorbidity. For many of these patients, 
despite locally advanced disease, they will die from causes 
other than breast cancer. For this reason, it could be difficult 
to assess long term survival of these patients.
Comparison of neoadjuvant endocrine 
therapy with chemotherapy
There are no large randomized studies comparing neoadjuvant 
endocrine therapy with chemotherapy, and little work has 
been done in this area since the patient populations who are 
most commonly treated with neoadjuvant chemotherapy 
tend to be premenopausal women with ER-negative International Journal of General Medicine 2009:2 138
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tumors. In contrast those treated with endocrine therapy 
tend to be elderly postmenopausal women with ER-positive 
tumors. Hence, indications of both therapies are certainly 
different. Nevertheless, two studies comparing neoadjuvant 
chemotherapy to neoadjuvant hormonotherapy have been 
reported by Semiglazov et al48,49 Postmenopausal women 
with ER-positive and/or PgR-positive breast cancer were 
assigned neoadjuvant treatment with either chemotherapy 
(doxorubicin and paclitaxel, 4 cycles) or endocrine therapy with 
aromatase inhibitors (anastrozole or exemestane, 3 months). 
The overall response rates (clinical and mammography) 
were statistically similar in the chemotherapy and endocrine 
groups. Neoadjuvant endocrine therapy with exemestane 
or anastrozole seems effective and safe in postmenopausal 
women with ER-positive breast cancer. Such treatment 
could be a reasonable alternative to chemotherapy for elderly 
women with ER-positive and/or PgR-positive breast cancer 
for whom the low toxicity of the regimen is considered an 
advantage. Further studies would be necessary to confirm 
these results.
exploration of neoadjuvant endocrine 
therapy with chemotherapy
In the same way, neoadjuvant endocrine therapy has been 
explored in combination with chemotherapy.
The Genari study group37 assessed the impact of a 
hormone and chemotherapy combination: exemestane 
associated to epirubicin, or docetaxel, or paclitaxel. Indeed, 
recent preclinical studies provided first evidence that 
hormonotherapy has high cytotoxic potential to subtoxic 
doses of chemotherapy when given concomitantly. Such a 
combination could potentially increase the CR rate with the 
benefit of excellent tolerability.
exploration of celecoxib and hormone 
therapy
The combination of celecoxib (a cyclooxygenase-2 inhibitor) 
and hormonotherapy needs to be explored. Cyclooxygenases 
are prostaglandin synthetase enzymes, which play a key 
role in mammary carcinogenesis. Prostaglandin E2 could 
contribute to an increase in estrogen synthesis in the 
tumor. A study was performed to investigate the efficacy 
of combining anti-aromatase therapy (exemestane and 
letrozole) and a cyclooxygenase-2 inhibitor (celecoxib) 
neoadjuvantly in hormone-sensitive postmenopausal breast 
cancer patients.50,51 Postmenopausal women were randomized 
into three groups. Group A patients received exemestane 
and celecoxib, group B patients were given exemestane 
alone and group C patients received letrozole alone. The 
maximum duration of treatment was 3 months. The clinical 
response rates were 61.5%, 60% and 54.5% respectively for 
groups A, B and C. Although the differences between the 
three groups were not significant, it would be interesting to 
conduct further studies to confirm these results. However, 
the general adversities of cyclooxygenase-2 inhibitors have 
to be taken into account.
Interest in neoadjuvant therapy
Although neoadjuvant chemotherapy has been widely 
employed to downstage locally advanced-stage breast cancer 
for quite a while, the use of primary systemic endocrine 
therapy is still considered something of a novelty. It is not, 
in fact, a standard treatment but could be useful for elderly 
women with operable, hormonosensitive, well differentiated 
and evoluating slowly (SBR I) tumor or for patients with lobu-
lar MSBR 1 carcinoma (low chemosensitivity). As for neoad-
juvant chemotherapy, neoadjuvant endocrine therapy enables 
the clinician to test the responsiveness of the malignant cells 
and provides an early opportunity to change the treatment 
if the tumor appears resistant. In contrast, toxicity is much 
lower with neoadjuvant endocrine therapy and this approach 
is extremely well tolerated, with very few patients having to 
discontinue the treatment because of side effects.
From a surgical perspective, the ability to perform less 
extensive surgery is an advantage especially considering 
the comorbidity and overall general health of the group of 
patients who tend to be treated with neoadjuvant endocrine 
therapy. Based on the poor local endocrine control observed 
in some trials, primary treatment alone without subsequent 
surgery at all cannot be recommended.14 The currently avail-
able data suggest that breast-conserving surgery followed 
by radiotherapy produces adequate local disease control in 
patients downstaged by neoadjuvant endocrine therapy.52,53 
The NSABP-B18 study has shown that patients achieving 
a pCR after neoadjuvant chemotherapy have a significantly 
better overall survival than the others, suggesting that the 
achievement of a pCR after neoadjuvant chemotherapy 
may serve as a surrogate marker for long-term survival.54 
In contrast to primary chemotherapy, pCRs for neoadjuvant 
endocrine therapy is generally considered as an exceptional 
event. Thus, further investigation would be necessary to 
determine which parameters may serve as surrogate markers 
for long-term survival in neoadjuvant endocrine therapy.
After the patient’s breast surgery, each case should 
be discussed in a collegial way for subsequent therapy. 
Chemotherapy could be proposed especially in case of large International Journal of General Medicine 2009:2 139
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tumoral residue and node involvement. Radiotherapy should 
be proposed at least in case of conservative surgery. The 
continuation of neoadjuvant hormone therapy as adjuvant 
treatment should be proposed to all patients presenting at 
least with a stable disease in the neoadjuvant phase.
Results of ongoing trials using neoadjuvant endocrine 
therapy are awaited with interest.
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